Transplant conditioning for AML patients with frailty or health issues
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of chemotherapy drugs before a stem cell transplant for people with acute myeloid leukemia (AML) in first remission who are not very fit or have other health problems. The goal is to make the transplant safer for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have acute myeloid leukemia (AML), but not a subtype called acute promyelocytic leukemia.
- Your leukemia is in first remission after initial chemotherapy.
- Your leukemia is not considered high-risk by current guidelines.
- You are not very active (ECOG score of 2 or more) or you have significant other health conditions (like heart, lung, or liver problems).
- You have a suitable donor for a stem cell transplant and are willing to have the transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a combination of two drugs (venetoclax and azacitidine) followed by a stem cell transplant from a donor for patients with a specific type of acute myeloid leukemia (AML) that has low bone marrow cell count or has developed from a prior blood disorder. The goal is to control the disease and give you a chance at a cure through transplantation.
This trial tests whether giving Venetoclax and Azacitidine (VA) after your first remission helps keep you in remission before a stem cell transplant. It's for people with intermediate-risk AML who are planning to have a donor transplant.
This trial tests a combination of total body irradiation and two chemotherapy drugs (busulfan and melphalan) given before a stem cell transplant. It is for people with acute myeloid leukemia that has come back or not responded to standard treatment.
This trial tests a new drug combination (SHR2554 plus azacitidine) given before a stem cell transplant to treat aggressive leukemia, myelodysplastic syndrome, or lymphoblastic leukemia. The goal is to reduce cancer cells before transplant and improve outcomes.
This trial tests a new drug combination to help people with relapsed or refractory acute myeloid leukemia (AML) get ready for a stem cell transplant. The goal is to make the transplant more effective and improve outcomes.
Hear when a new Leukemia, Myeloid, Acute(AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.